Response to Vemurafenib in Metastatic Triple-Negative Breast Cancer Harbouring a BRAF V600E Mutation: A Case Report and Electronically Captured Patient-Reported Outcome

Magdalena Pircher, Thomas Winder, Andreas Trojan, Magdalena Pircher, Thomas Winder, Andreas Trojan

Abstract

Effective treatment options are still scarce for metastatic triple-negative breast cancers. An increasing interest in the mutational landscape of this disease will facilitate novel therapeutic strategies in a variety of cancers. Here we report the case of a 38-year-old female patient who developed multiple lung metastasis of a triple-negative breast cancer 2 years after the completion of local therapy. When she progressed after two palliative chemotherapy lines and local electroporation, a next-generation sequencing revealed a BRAF V600E mutation for which we initiated therapy with the BRAF inhibitor vemurafenib. Radiological improvement was already evident after 3 months and has been ongoing for 19 months so far with very few side effects, as is demonstrated by electronically captured patient-reported outcomes. To our knowledge, this is the first published case where a BRAF V600E-mutated advanced triple-negative breast cancer was successfully treated with vemurafenib.

Keywords: BRAF V600E; Consilium smartphone app; Electronically captured patient-reported outcomes; Metastatic triple-negative breast cancer; Vemurafenib; ePROs.

Conflict of interest statement

A.T. is an initiator and stock owner of mobile Health AG, a startup company that operates the Consilium smartphone app. He serves as a chief medical officer for the startup company.

Copyright © 2021 by S. Karger AG, Basel.

Figures

Fig. 1
Fig. 1
History chart of ePROs as reported from the patient on her mobile device during treatment with vemurafenib. Blue, well-being; dark red, rash; light red, hand-foot syndrome; yellow, loss of appetite; olive green, nausea; orange, headache; green, cold symptoms; light purple, sensory disturbance; dark purple, gait disorder.
Fig. 2
Fig. 2
CT scan of the lung showing the lung metastasis in the right lung measuring 24.1 × 22.9 mm before vemurafenib treatment (a), and 19.4 × 13.1 mm 3 months after the initiation of vemurafenib treatment (b).

References

    1. Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9((2)):176–98.
    1. Munzone E, Gray KP, Fumagalli C, Guerini-Rocco E, Láng I, Ruhstaller T, et al. Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) trial 22-00. Breast Cancer Res Treat. 2018;170((2)):351–60.
    1. Garbe C, Eigentler TK. Vemurafenib. Recent Results Cancer Res. 2018;211:77–89.
    1. Kreitman RJ, Arons E. Update on hairy cell leukemia. Clin Adv Hematol Oncol. 2018;16((3)):205–15.
    1. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373((8)):726–36.
    1. Egbring M, Far E, Roos M, Dietrich M, Brauchbar M, Kullak-Ublick GA, et al. A mobile app to stabilize daily functional activity of breast cancer patients in collaboration with the physician: a randomized controlled clinical trial. J Med Internet Res. 2016;18((9)):e238.
    1. Trojan A, Huber U, Brauchbar M, Petrausch U. Consilium smartphone app for real-world electronically captured patient-reported outcome monitoring in cancer patients undergoing anti-PD-L1-directed treatment. Case Rep Oncol. 2020 May-Aug;13((2)):491–6.
    1. Trojan A, Bättig B, Mannhart M, Seifert B, Brauchbar M, Egbring M. Collaborative review of ePROs for shared reporting in breast cancer patients does not affect the number of data entries. Oncology. Forthcoming. 2020
    1. Seo T, Noguchi E, Yoshida M, Mori T, Tanioka M, Sudo K, et al. Response to dabrafenib and trametinib of a patient with metaplastic breast carcinoma harboring a BRAF V600E mutation. Case Rep Oncol Med. 2020;2020:2518383.
    1. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486((7403)):395–9.
    1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417((6892)):949–54.
    1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364((26)):2507–16.
    1. Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer. 2016;10:25–36.
    1. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377((6)):523–33.
    1. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379((22)):2108–21.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe